Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,245 shares of the company’s stock after selling 321 shares during the period. Kentucky Retirement Systems’ holdings in Moderna were worth $967,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB raised its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its stake in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares in the last quarter. Blue Trust Inc. lifted its position in Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares during the last quarter. Finally, EMC Capital Management boosted its stake in Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company’s stock valued at $52,000 after acquiring an additional 946 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 4.6 %

Shares of MRNA stock opened at $33.90 on Tuesday. The stock has a market capitalization of $13.05 billion, a PE ratio of -3.65 and a beta of 1.59. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The stock’s 50-day moving average price is $37.89 and its 200 day moving average price is $52.10.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 2,664 shares of company stock worth $115,210 in the last quarter. Company insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Wolfe Research initiated coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a report on Friday, February 14th. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.